Verastem (VSTM) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Verastem Revenue Highlights

Latest Revenue (Y)

$10.00M

Latest Revenue (Q)

$11.24M

Main Segment (Y)

Sale of COPIKTRA license and related assets

Verastem Revenue by Period

Verastem Revenue by Year

Date	Revenue	Change
2024-12-31	$10.00M	100.00%
2023-12-31	-	-100.00%
2022-12-31	$2.60M	26.45%
2021-12-31	$2.05M	-97.68%
2020-12-31	$88.52M	407.08%
2019-12-31	$17.46M	-34.67%
2018-12-31	$26.72M	100.00%
2017-12-31	-	100.00%
2016-12-31	-	100.00%
2015-12-31	-	100.00%
2014-12-31	-	100.00%
2013-12-31	-	100.00%
2012-12-31	-	100.00%
2011-12-31	-	100.00%
2010-12-31	-	-

Verastem generated $10.00M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 57.29% compared to the same period a year ago.

Verastem Revenue by Quarter

Date	Revenue	Change
2025-09-30	$11.24M	426.06%
2025-06-30	$2.14M	100.00%
2025-03-31	-	-100.00%
2024-12-31	$-9.98M	100.00%
2024-09-30	-	-100.00%
2024-06-30	$10.00M	100.00%
2024-03-31	-	-100.00%
2023-12-31	$114.00K	100.00%
2023-09-30	-	100.00%
2023-06-30	-	100.00%
2023-03-31	-	-100.00%
2022-12-31	$2.60M	100.00%
2022-09-30	-	100.00%
2022-06-30	-	-100.00%
2022-03-31	$2.60M	376.33%
2021-12-31	$545.00K	27150.00%
2021-09-30	$2.00K	-99.60%
2021-06-30	$500.00K	-50.30%
2021-03-31	$1.01M	98.81%
2020-12-31	$506.00K	-99.36%
2020-09-30	$78.65M	1726.03%
2020-06-30	$4.31M	-14.81%
2020-03-31	$5.06M	39.82%
2019-12-31	$3.62M	-59.96%
2019-09-30	$9.03M	188.01%
2019-06-30	$3.14M	87.67%
2019-03-31	$1.67M	38.10%
2018-12-31	$1.21M	-92.20%
2018-09-30	$15.51M	55.08%
2018-06-30	$10.00M	100.00%
2018-03-31	-	100.00%
2017-12-31	-	100.00%
2017-09-30	-	100.00%
2017-06-30	-	100.00%
2017-03-31	-	100.00%
2016-12-31	-	100.00%
2016-09-30	-	100.00%
2016-06-30	-	100.00%
2016-03-31	-	100.00%
2015-12-31	-	100.00%
2015-09-30	-	100.00%
2015-06-30	-	100.00%
2015-03-31	-	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	100.00%
2013-12-31	-	100.00%
2013-09-30	-	100.00%
2013-06-30	-	100.00%
2013-03-31	-	100.00%
2012-12-31	-	100.00%
2012-09-30	-	100.00%
2012-06-30	-	100.00%
2012-03-31	-	100.00%
2011-12-31	-	100.00%
2011-09-30	-	100.00%
2011-06-30	-	100.00%
2011-03-31	-	-

Verastem generated $11.24M in revenue during Q3 2025, up 426.06% compared to the previous quarter, and up 112.42% compared to the same period a year ago.

Verastem Revenue Breakdown

Verastem Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Sale of COPIKTRA license and related assets	$2.60M	-	-	-	-
Government rebates and other incentives	-	$67.00K	-	-	-
Copiktra license and related assets	-	$1.45M	-	-	-
Trade discounts and allowances	-	$23.00K	-	-	-
Returns	-	$31.00K	-	-	-
Product Revenue And Allowances Returns	-	-	$31.00K	$76.00K	$2.00K
Product Revenue Reserves And Allowances Trade Discounts And Allowances	-	-	$23.00K	$111.00K	$29.00K
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees	-	-	$2.08M	$255.00K	$88.00K
Product Revenue Reserves And Allowances Government Rebates And Other Incentives	-	-	$67.00K	$372.00K	$157.00K

Verastem's latest annual revenue breakdown by segment (product or service), as of Dec 22: Sale of COPIKTRA license and related assets (100.00%).

Quarterly Revenue by Product

Product/Service	Sep 25	Jun 25	Dec 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18	Sep 18
Government rebates and other incentives	$2.04M	$338.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Trade discounts and allowances	$467.00K	$29.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Returns	$165.00K	$26.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of COPIKTRA license and related assets	-	-	-	$2.60M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Copiktra license and related assets	-	-	-	-	$545.00K	-	-	-	-	-	-	-	-	-	-	-	-	-
Transition Services Revenue	-	-	-	-	-	$2.00K	-	-	-	-	-	-	-	-	-	-	-	-
Copiktra License And Related Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product Revenue And Allowances Returns	-	-	-	-	-	-	$28.00K	$28.00K	$25.00K	$126.00K	$326.00K	$123.00K	$5.00K	$71.00K	$8.00K	$4.00K	$1.00K	$1.00K
Product Revenue Reserves And Allowances Government Rebates And Other Incentives	-	-	-	-	-	-	-	$67.00K	$189.00K	$320.00K	$455.00K	$950.00K	$544.00K	$217.00K	$199.00K	$282.00K	$128.00K	$29.00K
Product Revenue Reserves And Allowances Trade Discounts And Allowances	-	-	-	-	-	-	$4.00K	$4.00K	$138.00K	$147.00K	$94.00K	$137.00K	$695.00K	$122.00K	$52.00K	$43.00K	$42.00K	$27.00K
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees	-	-	-	-	-	-	-	-	$270.00K	$296.00K	$135.00K	$239.00K	$1.85M	$281.00K	$153.00K	$104.00K	$48.00K	$72.00K

Verastem's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Government rebates and other incentives (76.30%), Trade discounts and allowances (17.51%), and Returns (6.19%).

Verastem Revenue Breakdown by Country

Quarterly Revenue by Country

Country	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Dec 18	Sep 18
Sale of COPIKTRA license and related assets	$2.60M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Copiktra license and related assets	-	$545.00K	-	-	-	-	-	-	-	-	-	-	-	-	-
Transition Services Revenue	-	-	$2.00K	-	-	-	-	-	-	-	-	-	-	-	-
Copiktra License And Related Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product Revenue And Allowances Returns	-	-	-	$28.00K	$28.00K	$25.00K	$126.00K	$326.00K	$123.00K	$5.00K	$71.00K	$8.00K	$4.00K	$1.00K	$1.00K
Product Revenue Reserves And Allowances Government Rebates And Other Incentives	-	-	-	-	$67.00K	$189.00K	$320.00K	$455.00K	$950.00K	$544.00K	$217.00K	$199.00K	$282.00K	$128.00K	$29.00K
Product Revenue Reserves And Allowances Trade Discounts And Allowances	-	-	-	$4.00K	$4.00K	$138.00K	$147.00K	$94.00K	$137.00K	$695.00K	$122.00K	$52.00K	$43.00K	$42.00K	$27.00K
Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees	-	-	-	-	-	$270.00K	$296.00K	$135.00K	$239.00K	$1.85M	$281.00K	$153.00K	$104.00K	$48.00K	$72.00K

Verastem's latest quarterly revenue breakdown by geography, as of Mar 22: Sale of COPIKTRA license and related assets (100.00%).

Verastem Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
PRTA	Prothena	$135.16M	$2.42M
GOSS	Gossamer Bio	$114.70M	$13.29M
RGNX	REGENXBIO	$83.33M	$29.73M
VSTM	Verastem	$10.00M	$11.24M
ABSI	Absci	$4.53M	$378.00K
CRVS	Corvus Pharmaceuticals	-	-
VTYX	Ventyx Biosciences	-	-
FDMT	4D Molecular Therapeutics	-	-
KALV	KalVista Pharmaceuticals	-	$13.69M
MLTX	MoonLake Immunotherapeutics	-	-
OLMA	Olema Pharmaceuticals	-	-

VSTM Revenue FAQ

What is Verastem’s yearly revenue?

Verastem's yearly revenue for 2024 was $10M, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. VSTM's yearly revenue for 2022 was $2.6M, representing an increase of 26.45% compared to 2021.

What is Verastem’s quarterly revenue?

Verastem's quarterly revenue for Q3 2025 was $11.24M, a 426.06% increase from the previous quarter (Q2 2025), and a 0% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $2.14M, a 100.00% increase from the previous quarter (Q1 2025), and a -78.63% decrease year-over-year (Q2 2024). VSTM's quarterly revenue for Q1 2025 was $0, a -100.00% decrease from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024).

What is Verastem’s revenue growth rate?

Verastem's revenue growth rate for the last 3 years (2022-2024) was 285.21%, and for the last 5 years (2020-2024) was -88.70%.

What are Verastem’s revenue streams?

Verastem's revenue streams in c 22 are Sale of COPIKTRA license and related assets

What is Verastem’s main source of revenue?

For the fiscal year ending Dec 22, the largest source of revenue of Verastem was Sale of COPIKTRA license and related assets. This segment made a revenue of $2.6M, representing 100.00% of the company's total revenue.